VistaGen Therapeutics's EBIT per Share for the
three
months ended in Dec. 2021 was $-0.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.19.
During the past 3 years, the average EBIT per Share Growth Rate was 40.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 44.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 9.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for VistaGen Therapeutics's EBIT per Share or its related term are showing as below:
VTGN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -616.4 Med: 26.45 Max: 49.5
Current: 40.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of VistaGen Therapeutics was 49.50% per year. The lowest was -616.40% per year. And the median was 26.45% per year.
VTGN's 3-Year EBIT Growth Rate is ranked better than 83.57% of 1175
companies
in the Biotechnology industry
Industry Median: 7.00
vs VTGN: 40.80
VistaGen Therapeutics's EBIT for the
three
months ended in Dec. 2021 was $-10.54 Mil.
VistaGen Therapeutics EBIT per Share Historical Data
The historical data trend for VistaGen Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
EBIT per Share
-1.30
-1.00
-0.86
-0.47
-0.21
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
EBIT per Share
-0.07
-0.03
-0.04
-0.07
-0.05
VistaGen Therapeutics EBIT per Share Calculation
EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.
Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.
VistaGen Therapeutics's EBIT per Share for the fiscal year that ended in Mar. 2021 is calculated as
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics (NAS:VTGN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
VistaGen Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.04(3.92%) Volume: 1,926,517 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
